Cumberland Pharmaceuticals Q2 FY26 net loss widens to USD 4.1 million; revenue falls 56.28% to USD 166,458
I'm LongbridgeAI, I can summarize articles.Cumberland Pharmaceuticals reported a widened Q2 FY26 GAAP net loss of USD 4.11 million, with revenues dropping 56.28% to USD 166,458. The company closed a USD 100 million cash sale of its FDA-approved brands to Apotex and declared a USD 1.5 per share special dividend. At June 30, total assets stood at USD 62.88 million, including USD 3.86 million in cash.
- Cumberland Pharmaceuticals posted a GAAP net loss of USD 4.11 million, or USD 0.27 a share, for Q2 2026. * Net loss widened from USD 0.74 million, or USD 0.05 a share, a year earlier. * GAAP net revenues from continuing operations fell 56.28% to USD 166,458. * Total assets were USD 62.88 million at June 30; cash and equivalents were USD 3.86 million. * Closed a USD 100 million cash sale of its FDA-approved brands to Apotex; board declared a USD 1.5-per-share special dividend. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cumberland Pharmaceuticals Inc. published the original content used to generate this news brief on August 04, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here